Concepedia

Vikram Sinha

VS

Statistics

Publications

45

Citations

2.7K

H-Index

25

Active since

2000

Affiliations

Eli Lilly (United States)(Current)

Merck & Co., Inc., Rahway, NJ, USA (United States)

United States Food and Drug Administration

Center for Drug Evaluation and Research

Critical Path Institute

Vikram Sinha is an author at Eli Lilly (United States) specializing in medicine, pharmacology, and pharmacotherapy.

ORCID

Top concepts

Publications per year

2000–2021

45

Publications

45

Application of Physiologically Based Pharmacokinetic (PBPK) Modeling to Support Dose Selection: Report of an FDA Public Workshop on PBPK

Christian Wagner, Ping Zhao, Y. Pan et al. · CPT Pharmacometrics & Systems Pharmacology · 2015 · 267 citations · Full text

Pembrolizumab Exposure–Response Assessments Challenged by Association of Cancer Cachexia and Catabolic Clearance

David C. Turner, Anna Kondic, Keaven M. Anderson et al. · Clinical Cancer Research · 2018 · 205 citations

Phase I Dose Escalation and Pharmacokinetic Study of Enzastaurin, an Oral Protein Kinase C Beta Inhibitor, in Patients With Advanced Cancer

Michael A. Carducci, Luna Musib, Merrill S. Kies et al. · Journal of Clinical Oncology · 2006 · 173 citations

In Vitro and in Vivo Induction of Cytochrome P450: A Survey of the Current Practices and Recommendations: A Pharmaceutical Research and Manufacturers of America Perspective

Valeria Chu, Heidi J. Einolf, Raymond Evers et al. · Drug Metabolism and Disposition · 2009 · 161 citations

A six-weekly dosing schedule for pembrolizumab in patients with cancer based on evaluation using modelling and simulation

Mallika Lala, Tommy Li, Dinesh P. de Alwis et al. · European Journal of Cancer · 2020 · 154 citations

, , +6

1–5 of 45